The Fly | BNBX

Today

BNB Plus Corp. announces Nasdaq delisting determination

BNBX

7:46 AM

Over a week ago

Crypto Currents: SoFi launches bank-issued stablecoin to consumers

+31

May 29, 9:38 AM

BNB Plus secures commitments for $4.1M in financing, initiates strategic review

BNBX

May 26, 8:15 AM

Crypto Currents: NY AG sues Coinbase, Gemini over prediction markets

+37

Apr 24, 9:42 AM

BNB Plus 'continues to execute' on operating initiatives amid strategic review

BNBX

Apr 23, 7:10 AM

BNB Plus Corp. completes production of $1.2M LineaDNA order

BNBX

Apr 23, 7:08 AM

BNB Plus Corp. receives non-compliance notice from Nasdaq

BNBX

Apr 20, 7:08 AM

BNB Plus Corp. announces review of strategic alternatives

BNBX

Apr 20, 7:08 AM

Crypto Currents: Meta plans entry into stablecoin space

+34

Feb 27, 10:06 AM

BNB Plus Corp. reports BNB token holdings valued at $10.7M as of February 23

Feb 24, 9:22 AM

BNB Plus Corp. receives two new orders for LineaDNA

BNBX

Feb 24, 9:17 AM

BNB Plus Corp. receives $1.2M order for LineaDNA

BNBX

Jan 5, 8:14 AM

BNB Plus Corp. ships largest single LineaDNA order

BNBX

Dec 18, 8:07 AM

BNB Plus says LineaRx subsidiary expected to approach profitability in Q1 2026

BNBX

Dec 9, 9:41 AM

BNB Plus acquires 3,349 additional BNB tokens for approximately $3M

Dec 9, 9:38 AM

Applied DNA chairperson Judy Murrah steps down, Josh Kruger to succeed

BNBX

Nov 17, 8:20 AM

Applied DNA Sciences files to sell 18.73M shares of common stock for holders

BNBX

Oct 30, 6:15 AM

Applied DNA announces private placement of up to $58M to start BNB treasury

Sep 29, 3:14 PM

No more stories

Proprietary DNA Technology Platforms: APDN possesses unique and patented DNA marking (SigNature DNA) and DNA production (LinearDNA) technologies that are difficult for competitors to replicate.

Robust Intellectual Property Portfolio: The company holds numerous patents protecting its core innovations, creating a significant barrier to entry for potential competitors in the DNA-based authentication and biomanufacturing space.

Forensics-Grade Authentication Capabilities: Its SigNature DNA markers offer an unparalleled level of security and traceability, making counterfeiting or diversion extremely difficult to achieve without detection.

Limited Market Adoption and Competition: The company's DNA-based security and diagnostic technologies may not achieve widespread commercial acceptance, or face intense competition from existing or new market entrants offering alternative solutions.

Dependence on Key Customers and Contracts: A significant portion of APDN's revenue may be derived from a limited number of customers or large contracts, and the loss or non-renewal of any such contract could materially impact its financial results.

Intellectual Property Protection Risks: The success of APDN depends heavily on its ability to protect its proprietary technologies through patents and other intellectual property rights, and any failure to do so could allow competitors to use similar technologies, eroding market share.

Proprietary DNA Technology Platforms: APDN possesses unique and patented DNA marking (SigNature DNA) and DNA production (LinearDNA) technologies that are difficult for competitors to replicate.